Anti-CD274 Antibody, Non-Fucosylated (AMP-224) (CAT#: BioBet-653ZP) Datasheet

CD274

CD274 molecule

The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor is required for generation and long-term maintenance of T cell immunity. It binds to ligand CD70, and plays a key role in regulating B-cell activation and immunoglobulin synthesis. This receptor transduces signals that lead to the activation of NF-kappaB and MAPK8/JNK. Adaptor proteins TRAF2 and TRAF5 have been shown to mediate the signaling process of this receptor. CD27-binding protein (SIVA), a proapoptotic protein, can bind to this receptor and is thought to play an important role in the apoptosis induced by this receptor.

CD274; CD274 molecule; B7-H; B7H1; PDL1; PD-L1; PDCD1L1; PDCD1LG1; programmed cell death 1 ligand 1; B7 homolog 1; CD274 antigen; PDCD1 ligand 1; programmed death ligand 1

Plasma membrane, Endosome

Diseases associated with CD274 include Testicular Lymphoma and Smoldering Myeloma.

Its related pathways are Innate Immune System and Class I MHC mediated antigen processing and presentation.

It plays a key role in inducing and maintaining immune tolerance to oneself. As a ligand of inhibitory receptor PDCD1/PD-1, it regulates the T cell activation threshold and limits the T cell response. Through an unknown activation receptor, it is possible to stimulate a subset of T cells to mainly produce interleukin 10 (IL10).Tumors use pdcd1-mediated inhibition to weaken anti-tumor immunity and escape the destruction of the immune system, thereby promoting tumor survival. The interaction with PDCD1/PD-1 inhibits the effector function of cytotoxic T lymphocytes (CTLs) (similar). The blockade of the pdcd1 mediated pathway leads to the reversal of the exhausted T cell phenotype and the normalization of the anti-tumor response, which provides a theoretical basis for cancer immunotherapy (through similarity).

Immune System antibody

1.Ubiquitinated; STUB1 likely mediates polyubiquitination of PD-L1/CD274 triggering its degradation. 2.Modification sites at PhosphoSitePlus 3.Glycosylation at Asn35, Asn192, Asn200, and Asn219

Protein Based Therapies
Monoclonal antibody (mAb)

IgG

AMP-224

Human

Human

AMP-224 is a PD-1 inhibitor, in combination with stereotactic body radiation therapy in people with metastatic colorectal cancer.

Cancer

Cancer